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Introduction
Certain drugs that block the renin-angiotensin-
aldosterone system (RAAS), namely angiotensin
converting enzyme inhibitors (ACE-I) and spirono-
lactone, have been shown to improve symptoms,
reduce hospital admission rates and increase sur-
vival in patients with chronic heart failure (CHF).1–5
Consequently, angiotensin II (Ang II) type 1 recep-
tor antagonists or Ang II type 1 receptor (AT1-
receptor) blockers (ARBs) may also have a role in
the treatment of CHF. Two therapeutic strategies
have been considered for ARBs, the first as an alter-
native to ACE-I6–9 and the second in combination
with ACE-I.10–12 Interestingly, the rationale behind
these strategies is quite different. In the first, the
kinase II property of ACE is considered disadvan-
tageous, in that bradykinin is directly or indirectly
blamed for the undesirable effects of ACE-I such as
cough and angio-oedema.6,7 The second strategy
sees bradykinin as a desirable substance, with
vasodilator, anti-thrombotic and growth inhibiting
properties.10–12 Both strategies,however, regard ACE-
I as sub-optimal antagonists of the action of Ang II,
reflecting the belief that non-ACE pathways also
contribute to the generation of Ang II (and this can
only be blocked by an ARB).13–15 An even more the-
oretical difference between ACE-I and ARBs con-
cerns the postulated role of the Ang II type 2 recep-
tor (AT2-receptor). This receptor is considered by
some to exert the opposite effects to the AT1-recep-
tor.16 ACE inhibition leads to reduced stimulation of
both types of Ang II receptor, whereas selective AT1-
receptor blockade, in theory, leads to hyperstimula-
tion of the unblocked AT2-receptor. The alternative
strategy of combination ACE-I and ARB therapy in
CHF will not have this effect (Figure 1).
From scientific theory to clinical
trials – ELITE-II
The theory that ARBs might be a more efficacious
(blocking non-ACE-generated Ang II) and better
tolerated (no kininase II inhibition) alternative to
ACE-I was definitively tested in the second
Evaluation of Losartan In the Elderly (ELITE-II)
trial.8,9 This study compared losartan,50 mg  once-
daily, to captopril, 50 mg three times daily, in 3152
patients with NYHA Class II-IV CHF (Table 1).
Despite being better tolerated, losartan was not
more efficacious than captopril (Table 2).9 ELITE-
II was neither designed nor powered to test for
equivalence (losartan as good as captopril) or
non-inferiority (losartan no worse than capto-
pril).17 ELITE-II, therefore, tells us that ARBs
should not replace ACE-I as an alternative means
of suppressing the RAAS in CHF. There is,
however, some concern that the dose of losartan
Figure 1  Effects of ACE inhibition and angiotensin II type 1 receptor blockade on angiotensin receptor stimulation
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and dosing frequency, may not have been suffi-
cient to adequately block the RAAS in this trial.
Combination therapy rather than
alternative therapy?
The second definitive clinical trial with an ARB in
CHF adopted the ‘add-on’ rather than ‘alternative’
strategy.12 In the Valsartan Heart Failure Trial (Val-
HeFT), 5010 patients with NYHA Class II-IV CHF
(Table 1) were randomised to receive either
placebo or valsartan, (target dose 160 mg twice-
daily), in addition to background therapy. 93% of
patients were taking an ACE-I and 34% a beta-
blocker (Table 1).The co-primary endpoints were
all-cause mortality and a mortality/morbidity end-
point (hospitalisation for CHF, resuscitated sudden
death, administration of intravenous vasodilator or
inotropic therapy for CHF for ≥4 hours). The
results of Val-HeFT are shown in Table 3 (present-
ed by Professor Jay Cohn at the 50th Scientific
Session of the American College of Cardiology,
Orlando, Florida, March, 2001).All-cause mortality
was not different between groups; there was,
however, a relative risk reduction in the combined
mortality/morbidity endpoint of approximately
13% (p=0.009) in the valsartan group. This was
mainly because of a 27% reduction in the risk of CHF
hospitalisation (p=0.00001). There were also signif-
icant improvements in other secondary endpoints,
such as quality of life, signs and symptoms and left
ventricular ejection fraction, in the valsartan group.
At face value,Val-HeFT, therefore, seems to be a
‘positive’ trial. However, two subgroup analyses
have probably made this interpretation too sim-
plistic. Firstly, a very large (45%) reduction in mor-
tality/morbidity in the small (7%) subset of
patients not taking an ACE-I at baseline has led
some to question whether most of the benefit in
the overall Val-HeFT study population was con-
fined to this group. Secondly, there was a trend
towards an increased rate of mortality/morbidity
events in the beta-blocker subgroup of patients
given valsartan. Further analysis suggests that this
effect was most clearly observed in patients taking
both an ACE-I and beta-blocker at baseline (Figure
2). Clearly, as beta-blockers, along with ACE-I,
are now recommended first line therapy for
all patients with CHF, this finding is of great
concern.
It must be emphasised, however, that retro-
spective subgroup analysis of this type can be very
misleading.18 Often, apparent differences in
response merely reflect the small numbers of
patients in certain subsets and the play of chance.
Proper interpretation requires assessment of inter-
nal and external consistency and biological plausi-
bility. The first of these is impossible as the full
data (e.g. on left ventricular remodelling, neurohu-
moral responses, etc.) are not available. There is
conflicting evidence when it comes to external
consistency. A directionally similar interaction
with beta-blockers was noted in ELITE-II. No con-
cerns, however, have been raised in relation to the
very large, on-going valsartan in acute myocardial
infarction trial (VALIANT), in which patients are
randomised to valsartan, captopril or their combi-
nation and where more than 70% are taking a
beta-blocker.19
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Table 1  Clinical characteristics of patients enrolled in
ELITE-II and Val-HeFT.
ELITE-II Val-HeFT
Number of patients 3152 5010
Mean age (yr) 71 63
Males (%) 70 80
NYHA Class (%)
II 52 62
III 43 36
IV 5 2
LVEF (%) 31 27
Concomitant diagnoses (%)
Coronary aetiology* 79 57
Hypertension 49 -
Atrial fibrillation 30 -
Diabetes mellitus 24 12
Drug treatment (%)
Diuretic 78 86
ACE inhibitor -** 93
Cardiac glycoside 50 67
Beta-blocker 22 34
* ‘history of ischaemia’ in ELITE-II
** patients randomised to either losartan or captopril
(23% of patients had received prior ACE inhibitor)
Table 2  ELITE-II endpoints.
Endpoint Number of patients HR (95%CI) p-value
Losartan Captopril
n=1578 n=1574
All-cause mortality 280 (17.7%) 250 (15.9%) 1.13 0.16
(0.95–1.35)
Sudden death or 142 (9.0%) 115 (7.3%) 1.25 0.08
resuscitated cardiac arrest (0.98–1.60)
Combined total mortality or 752 (47.7%) 707 (44.9%) 1.07 0.18
hospitalisation for any reason (0.97–1.19)
Hospital admissions (all-causes) 659 (41.8%) 638 (40.5%) 1.04 0.45
(0.94–1.16)
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There is also no good, biologically plausible
explanation for an adverse interaction between
beta-blockers and ARBs (or the combination of
beta-blockers and ACE-I and an ARB).
What is the place of ARBs in the 
management of CHF after ELITE-II
and Val-HeFT?
The totality of the currently available evidence
suggests that ARBs may be a useful alternative to
ACE-I in patients intolerant of the latter. This
assumption is, however, being formally tested in
one arm of the Candesartan in Heart Failure:
Assessment of Reduction in Mortality and
Morbidity (CHARM) programme.20
ARBs are not a general alternative to ACE-I,
which remain first line therapy for all patients
with CHF who can tolerate them.
The more difficult question is whether to rec-
ommend an ARB in addition to an ACE-I?
Presently, in patients taking a beta-blocker (and
that should be most patients) this is not advisable.
Again, however, the CHARM programme, which
has an ACE-I/ARB combination arm (in which
around half of patients are receiving a beta-
blocker), and VALIANT trial will give more infor-
mation on this issue in the next two to three
years.19,20 In patients not taking a beta-blocker,
adding an ARB to background ACE-I treatment
seems an acceptable strategy. The last and hardest
of all scenarios to judge is that where the patient
cannot take an ACE-I but can take a beta-blocker.
Should such a patient receive an ARB as well as a
beta-blocker?  The subgroup analysis shown in
Figure 2 suggests ‘yes’ but the most cautious inter-
pretation of the beta-blocker/ARB interaction
question would say ‘wait for CHARM and VALIANT
to finish and just use a beta-blocker at present’.
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Table 3  Val-HeFT:endpoints.
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Figure 2  Combined all-cause mortality and morbidity
ACE inhibitor/beta-blocker subgroups.
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